共 50 条
Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells
被引:0
|作者:
Mototsugu Oya
Masafumi Ohtsubo
Atsushi Takayanagi
Masaaki Tachibana
Nobuyoshi Shimizu
Masaru Murai
机构:
[1] Keio University School of Medicine,Department of Urology
[2] Shinjuku-ku,Department of Molecular Biology
[3] Keio University School of Medicine,undefined
[4] Shinjuku-ku,undefined
来源:
Oncogene
|
2001年
/
20卷
关键词:
renal cell carcinoma;
TRAIL;
NF-κB;
IκBα;
apoptosis;
D O I:
暂无
中图分类号:
学科分类号:
摘要:
TRAIL has gained much attention for its specific induction of apoptosis in cancer cells but not in normal cells. This phenomenon has been explained thus: that cancer cells dominantly express death receptors while normal cells express decoy receptors. However, recent reports have shown that some cancer cell lines are resistant to TRAIL-induced apoptosis despite the absence of decoy receptors and the presence of death receptors. This suggested the existance of an inhibitory factor. We herein showed that NF-κB is a key molecule underlying the TRAIL-resistant mechanism in renal cell carcinoma (RCC) cell lines. We observed that NF-κB is constitutively activated in resistant cell lines. Forced expression of antisense cDNA of IκBα, a specific inhibitor of NF-κB, in TRAIL-sensitive cell lines with a low NF-κB activity result in constitutive activation of NF-κB and resistance to TRAIL-induced apoptosis. Adenoviral expression of a stable form of IκBα in the TRAIL-resistant cell lines induced apoptosis. These data suggest that RCC can be classified into two subsets: TRAIL-sensitive RCC with a low NF-κB activity and TRAIL-resistant RCC with constitutively activated NF-κB. In the former group TRAIL can be a treatment option, while in the latter group a molecular approach targeting NF-κB appears to be a promising therapy.
引用
收藏
页码:3888 / 3896
页数:8
相关论文